RT Journal Article
SR Electronic
T1 Modelling the Impact of Nationwide BCG Vaccine Recommendations on COVID-19 Transmission, Severity, and Mortality
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.10.20097121
DO 10.1101/2020.05.10.20097121
A1 Shah, Nita H.
A1 Suthar, Ankush H.
A1 Satia, Moksha H.
A1 Shah, Yash
A1 Shukla, Nehal
A1 Shukla, Jagdish
A1 Shukla, Dhairya
YR 2020
UL http://medrxiv.org/content/early/2020/05/14/2020.05.10.20097121.abstract
AB COVID-19 was declared as pandemic on 11th March 2020 by WHO. There are apparent dissimilarities in incidence and mortality of COVID-19 cases in different parts of world. Developing countries in Asia and Africa with fragile health system have shown lower incidence and mortality compared to developed countries with superior health system in Europe and America. Most countries in Asia and Africa have national BCG vaccination program while Europe and America do not have such program, or have ceased it. At present, there is no known therapy to treat COVID-19 disease. There is no vaccine available currently to prevent COVID-19 disease. As mathematical modelling is ideal for predicting the rate of disease transmission as well as evaluating efficacy of possible public health prevention measures, we have created a mathematical model with seven compartments to understand nationwide BCG vaccine recommendation on COVID-19 transmission, severity and mortality. We have computed two basic reproduction number, one at vaccine free equilibrium point and other at non-vaccine free equilibrium point and carried out local stability, sensitivity and numerical analysis. Our result showed that individuals with BCG vaccinations have lower risk of getting COVID-19 infection, shorter hospital stays, and increased rate of recovery. Furthermore, countries with long-standing universal BCG vaccination policies have reduced incidence, mortality, and severity of COVID-19. Further research will focus on exploring the immediate benefits of vaccination to healthcare workers and patients as well as benefits of BCG re-vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSecond author (AHS) is funded by a Junior Research Fellowship from the Council of Scientific & Industrial Research (file no.-09/070(0061)/2019-EMR-I) and First three authors are thankful to DST-FIST file # MSI-097 for technical support to the Department of Mathematics, Gujarat University.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOur conclusion is based on the data derived from our above mathematical calculations which are available to readers.